Overview

Photos from Acceleration 2012

This third annual Acceleration conference was a resounding success. Almost 200 executives and thought leaders from the biotechnology, pharmaceutical, medical device, diagnostic, healthIT and healthcare fields gathered to discuss the changing landscape of value creation in light of the current venture funding environment and the impact of the Affordable Care Act. A recap summarizing key themes and trends from the program is available here. We look forward to seeing you at Acceleration 2014.

Acceleration connects investors, entrepreneurs and industry executives in biotech, pharma, device and healthcare who are focused on innovation and investment for growth. Join key thought leaders to examine exit transactions and how the industry views value creation in a post-ACA world.

KEYNOTE SPEAKER:

Healthcare: Trends in Mergers and Acquisitions

JonathanNorrisJonathan Norris
Managing Director
Silicon Valley Bank

Jonathan Norris will present findings from Silicon Valley Bank’s annual report on healthcare venture trends, examining early stage investment, venture fundraising, exit deals, and industry forecasts.

For a copy of Jonathan’s presentation Healthcare Venture: State of the Industry Update, click here.

PANEL: Exits for Life Science Companies

How the Affordable Care Act is changing the definition of value for entrepreneurs, investors and acquirers. The panel will explore the impact of the ACA – with its focus on patient outcomes and cost control – on the building, financing and acquisition of life science companies.

Speakers:

Ambar Bhattacharyya
Vice President
Bessemer Venture Partners

Michael Powell, PhD
General Partner
Sofinnova Ventures

Laurel Sweeney
Senior Director, Health Economics and Reimbursement
Philips Healthcare

Moderator:

Michelle L. Basil
Chair, Life Sciences Group
Nutter McClennen & Fish LLP

Interview with CEO

Barbara Fox, Ph.D., Founder & CEO of Avaxia Biologics, will be interviewed by Angel investor and Board Member, Henry Kay, to describe the challenges faced, and solutions identified, in conceptualizing, funding and growing a cutting edge biotechnology company.

COCKTAILS & NETWORKING

Healthcare Venture: State of the Industry Update